| Literature DB >> 34664196 |
Gregorio Arellano-Gutiérrez1, Edmundo Humberto Aldana-Zaragoza2, Abraham Pérez-Fabián3.
Abstract
COVID-19 pandemic is one of the most devastating worldwide crises in recent years. During this pandemic, people have been exposed to products that have not been proven to be safe and effective against COVID-19. We present an adult chronic consumer of chlorine dioxide, in which a fatal outcome is described. This case demonstrates that for people searching products to protect themselves from COVID-19, unregulated access to industrial disinfectants represents a dangerous alternative. To date, there is no scientific evidence to uphold the use of chlorine dioxide or chlorine derivatives as preventive or therapeutic agents against COVID-19. Researchers and general population must take into consideration the fatal possible consequences of not following communications and warnings from health authorities and government institutions.Entities:
Keywords: COVID-19; Chlorine dioxide; Ingestion; Perforation; SARS-CoV-2
Mesh:
Substances:
Year: 2021 PMID: 34664196 PMCID: PMC8522852 DOI: 10.1007/s12328-021-01527-y
Source DB: PubMed Journal: Clin J Gastroenterol ISSN: 1865-7265
Fig. 1Abdominal CT demonstrates free intraperitoneal air and fluid secondary to hollow viscus rupture
Fig. 2Small bowel resected segment (jejunum) measuring 40.0 cm. Full thickness necrosis and perforation in the anti-mesenteric area is evident (A). Jejunal perforation with regular edges measuring 1.0 × 1.0 cm (B)
Fig. 3Histopathological findings. Ulceration and denudation of the epithelium, with the presence of conserved epithelial cells. Serous layer with destruction of the parenchyma (A). Chronic inflammation of the serous layer with neutrophilic infiltrate. Inflammation and severe changes due to tissue necrosis in the mucosa are present (B). Muscle layers with chemical destruction and neutrophilic infiltration in the serous layer (C)
Data analysis of 53 patients associated to chlorine dioxide exposure
| Purpose for use | Cases (%) |
|---|---|
| Infectious disease | 13.2 |
| Cure all/supplement | 9.4 |
| Accidental exposure | 9.4 |
| Detoxification | 7.5 |
| Toothache | 3.8 |
| Constipation | 3.8 |
| Sinus pain | 1.9 |
| Self-harm | 1.9 |
| Lymphoma | 1.9 |
| Autism | 1.9 |
| Not documented | 45.3 |
| Related clinical effects | |
| Vomiting | 49.1 |
| Nausea | 28.3 |
| Abdominal pain | 22.6 |
| Diarrhea | 20.8 |
| Oral or throat irritation, Cough, choke | 17 |
| Burns (any degree) | 7.5 |
| Ocular (irritation/pain/red eye/conjunctivitis) | 5.7 |
| Other | 11.3 |
| Chronicity | |
| Acute | 84.9 |
| Acute-on-chronic | 1.9 |
| Chronic | 11.3 |
| Unknown | 1.9 |
| Time to onset | |
| < 1 h | 30.2 |
| > 1 h to < 1 day | 45.2 |
| > 1 day to ≤ 1 week | 9.4 |
| 2 months | 1.9 |
| Unknown | 13.2 |
| Gender | |
| Female | 62.3 |
| Male | 37.7 |
| Route of administration | |
| Oral ingestion | 83 |
| Other (inhalation, dermal, rectal, and ocular) | 17 |
Modified from reference [28]